The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for avalglucosidase alfa (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
avalglucosidase alfa
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Powder for injection
Indication
Avalglucosidase alfa is intended for long-term enzyme replacement therapy (ERT) for the treatment of patients with Pompe disease (acid α-glucosidase deficiency)
Therapeutic area
Inherited metabolic disorders